DD and others, can we do some analysis of the gains to MNTA from a deal with TEVA? For starters, what would MNTA revenues from M-Enox drop to with the approval and sale of T-Enox?
Thank you for your insight. I'm thinking (could be wrong) that NVS/MNTA will take their chances in court. As you previously have pointed out, NVS/MNTA patent lawyers I'm sure feel very confident they will succeed in court. Why settle out of court giving TEVA all the Copaxone sales when NVS/MNTA is prepared to launch? Best to all.
News 
Market Data 
Discover 
AI
